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Abstract: Overexpression of P-glycoprotein (P-gp) and other ATP-binding cassette (ABC) transporters
in multidrug resistant (MDR) cancer cells is responsible for the reduction of intracellular drug
accumulation, thus decreasing the efficacy of chemotherapeutics. P-gp is also found at endothelial
cells’ membrane of the blood-brain barrier, where it limits drug delivery to central nervous system
(CNS) tumors. We have previously developed a set of pyrazolo[3,4-d]pyrimidines and their prodrugs
as novel Src tyrosine kinase inhibitors (TKIs), showing a significant activity against CNS tumors in
in vivo. Here we investigated the interaction of the most promising pair of drug/prodrug with P-gp
at the cellular level. The tested compounds were found to increase the intracellular accumulation
of Rho 123, and to enhance the efficacy of paclitaxel in P-gp overexpressing cells. Encouraging
pharmacokinetics properties and tolerability in vivo were also observed. Our findings revealed a
novel role of pyrazolo[3,4-d]pyrimidines which may be useful for developing a new effective therapy
in MDR cancer treatment, particularly against glioblastoma.
Keywords: glioblastoma; multidrug resistance; P-gp inhibitors; Src inhibitors; in vitro ADME;
pharmacokinetics; brain distribution; tolerability
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1. Introduction
Multidrug resistance (MDR) is a severe and pervasive clinical problem which actually represents
the leading cause of cancer treatment failure. MDR occurs when cancer cells develop resistance
to structurally and mechanistically unrelated classes of anticancer drugs [1] and involves several
complex mechanisms [2], among which the overexpression of ATP-binding cassette (ABC) transporters
is the most prominent. ABC transporters regulate the ATP-dependent eﬄux of toxic endogenous
molecules and chemotherapeutics out of the cell. Among the 49 ABC transporters known so far,
P-glycoprotein (P-gp, MDR1, ABCB1), multi-drug resistance protein 1 (MRP1, ABCC1) and breast
cancer resistance protein (BCRP, ABCG2) appear to play the most important roles in inducing resistance
in several cancers, such as lung, breast, colon, ovarian, central nervous system (CNS) cancers, and
melanomas [3–5]. Moreover, ABC eﬄux transporters are also found in excretory epithelial cells of
the gastrointestinal tract (GI), kidney, liver, and in endothelial cells of physiological barriers such as
the blood-brain barrier (BBB) [6,7]. Thus, drug eﬄux pumps are key elements for drug delivery and
efficacy in target tumor cells, as well as for CNS distribution. Therefore, their modulation offers a novel
strategy to enhance the penetration and improve the efficacy of drugs into the brain, especially for
drug-resistant CNS tumors [8].
Glioblastoma Multiforme (GBM) is the most aggressive (World Health Organization grade IV)
brain tumor in adults and the most frequent one. The majority of GBM patients do not live for longer
than 1 year [9] and the average 5-year survival rate for patients is less than 3% [10]. After standard
treatment, which requires surgical resection followed by concomitant radiotherapy and temozolomide
therapy, fatal relapses commonly occur, and recurrent GBM tends to be even more aggressive and
resistant to medical treatment than its primary counterpart [11].
In the past two decades, molecular characterization of genomic alterations in GBM has offered an
array of altered pathways that can be specifically targeted. Given their pivotal role in tumorigenesis,
tyrosine kinases (TKs) have been indicated as an interesting target to treat several cancers [12]. Abnormal
or deregulated activity of at least one TK is responsible for oncogenic activity across a broad range of
tumors, and in particular of 67.3% of GBM [13]. Coordinately, small-molecule compounds that inhibit the
kinase domain of specific TKs have been widely introduced into clinical practice for a number of advanced
solid cancers in the last two decades [14]. However, to date, kinase inhibitors have shown minimal efficacy
in GBM clinical trials due to the unique characteristics of GBM: (i.) its infiltrative, invasive, and aggressive
nature; (ii.) intrinsic and/or acquired drug resistance; (iii.) unsuccessful drug delivery across BBB [15].
In the last years, we have focused on the development of novel TK inhibitors based on the
pyrazolo[3,4-d]pyrimidine scaffold. These compounds act as ATP-competitive tyrosine kinase
inhibitors [16] against the Src-Family Kinases (SFKs) [17]. SFKs are involved in the regulation
of cell proliferation, survival, invasion and angiogenesis, thus playing a crucial role in the
development and progression of many cancer types, including GBM [18]. In particular, elevated Src
activity/phosphorylation are found in GBM samples and cancer cell lines [19,20].
The implication of SFKs in glioma biology has led to the clinical evaluation of the SFK inhibitor-
dasatinib, as a novel therapeutic option in particular for recurrent GBM [21–23]. However, its usefulness
was limited by pharmacokinetics aspects, i.e., short half-life, sub-optimal CNS penetration, and inadequate
delivery to the tumor. In vitro and in vivo studies have demonstrated that dasatinib is a substrate for the
efflux transporters P-gp and BCRP, which are highly expressed in the BBB [24,25] and GBM cells [26].
It was shown that TKIs interact with eﬄux transporters either as their substrates or inhibitors.
In some cases, TKIs which are substrates for eﬄux transporters, when applied in high concentrations,
can act as inhibitors of transporters [27–30]. Some of TKIs acting as ABC transporters inhibitors either
entered clinical trials or were clinically approved [31–33]. TKIs may also modulate MDR by regulating
the expression levels of MDR proteins [34]. Considering the dual inhibitory potential of TKIs, these
anticancer agents are valuable for combining with other chemotherapeutics [35].
The inhibition of drug eﬄux transporters often alters the pharmacokinetic properties of the
co-administered substrate drug. The increase of oral bioavailability or decrease in biliary excretion and
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clearance usually result in higher systemic exposure and toxicity. Thus, lapatinib and gefitinib have
been reported to strengthen the bioavailability of certain antitumor agents [36,37].
The anticancer activity of pyrazolo[3,4-d]pyrimidines has been proved in vitro against several
cancer cell lines, both from solid tumors (osteosarcoma [38], prostate [39], neuroblastoma [40,41],
glioblastoma [42,43], rhabdomyosarcoma [44], mesothelioma [45], medulloblastoma [46], medullary
thyroid carcinoma [47]) and hematological tumors (leukemia [48] and Burkitt lymphomas [49]), and
further confirmed by in vivo studies in mouse models of neuroblastoma [40], leukemia [48], and
glioblastoma [50]. In particular, the combination of compound Si306 (Figure 1a), a pyrazolo[3,4-
d]pyrimidine derivative with radiotherapy strongly potentiated the suppression of U87 xenograft
growth in nude mice with respect to control and single treatments [50]. Moreover, following
intraperitoneal (i.p.) injection, Si306 brain concentration progressively increased during the following
24 h, and the compound appeared to accumulate in the brain. Single oral treatment with Si306
prolonged by 30% the survival of mice orthotopically injected with U87 cells [50]. Overall, this evidence
confirmed the ability of Si306 to efficiently reach the brain. Analogous results were obtained with the
prodrug of Si306 (pro-Si306, Figure 1b), which showed an enhanced solubility and good efficacy in an
orthotopic model of GBM with respect to the parental drug [50].
Cancers 2019, 11, x 3 of 20 
 
clearance usually result in higher systemic exposure and toxicity. Thus, lapatinib and gefitinib have 
been reported to strengthen the bioavailability of certain antitumor agents [36,37]. 
The anticancer activity of pyrazolo[3,4-d]pyrimidines has been proved in vitro against several 
cancer cell lines, both from solid tumors (osteosarcoma [38], prostate [39], neuroblastoma [40,41], 
glioblastoma [42,43], rhabdomyosarcoma [44], mesothelioma [45], medulloblastoma [46], medullary 
thyroid carcinoma [47]) and hematological tumors (leukemia [48] and Burkitt lymphomas [49]), and 
further confirmed by in vivo studies in mouse models of neuroblastoma [40], leukemia [48], and 
glioblastoma [50]. In particular, the combination of compound Si306 (Figure 1a), a pyrazolo[3,4-
d]pyrimidine derivative with radiotherapy strongly potentiated the suppression of U87 xenograft 
growth in nude mice with respect to control and single treatments [50]. Moreover, following 
intraperitoneal (i.p.) injection, Si306 brain concentration progressively increased during the following 
24 h, and the compound appeared to accumulate in the brain. Single oral treatment with Si306 
prolonged by 30% the survival of mice orthotopically injected with U87 cells [50]. Overall, this 
evidence confirmed the ability of Si306 to efficiently reach the brain. Analogous results were obtained 
with the prodrug of Si306 (pro-Si306, Figure 1b), which showed an enhanced solubility and good 
efficacy in an orthotopic model of GBM with respect to the parental drug [50]. 
 
 
(a) (b) 
Figure 1. Molecular structure of Si306 (a) and pro-Si306 (b). 
In this study, we investigated the effect of Si306 and its prodrug on P-gp-mediated efflux, 
interaction with cytochrome P450 isoform 3A4 (CYP3A4), and suggested their potential use as 
sensitizers in combination with chemotherapeutics. Additionally, in order to widen the 
characterization of Si306, which may be useful for the design of preclinical studies, we explored its 
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sensitizers in combination with chemotherapeutics. Additionally, in order to widen the characterization
of Si306, which may be useful for the design of preclinical studies, we explored its plasma and brain
phar acokinetics after both oral (p.o.) administration and intravenous (i.v.) injection, including
plasma protein binding, and its acute toxicity in mice.
2. Results
2.1. Cel Growth Inhibition by asati i , i
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Table 1. Sensitivity of glioblastoma ultiforme (GBM) cells to c-Src inhibitors expressed as half maximal
inhibitory concentration (IC50) values ± S.D. (µM), calculated from three independent experiments (n = 3).
Compounds U87 U87-TxR LN-229
Dasatinib 6.143 ± 0.464 8.516 ± 0.691 24.682 ± 1.027
Si306 3.081 ± 0.260 4.775 0.322 8.008 ± 0.574
Pro-Si306 3.045 ± 0.343 3.419 0.359 3.074 ± 0.272
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Si306 and pro-Si306 exerted identical growth inhibitory effect in U87 cells with approximate IC50
values of 3 µM. Pro-Si306 retained unchanged efficacy in U87-TxR cells and LN-229, while IC50 for
Si306 increased to 4.8 µM for U87-TxR and to 8.0 µM for LN-229. The IC50 values for dasatinib were
6.1 µM, 8.5 µM and 24.7 µM in U87, U87-TxR and LN-229 cells, respectively. Cell viability inhibition
by Si306 and pro-Si306 was evaluated also on other GBM cell lines and results are shown in Table S1.
2.2. Influence of c-Src Inhibitors on P-gp Expression and Activity
The expression of mRNA mdr1 was unaffected by all examined c-Src inhibitors (Figure 2a), while
only dasatinib increased P-gp expression (Figure 2b). According to rhodamine (Rho) 123 (fluorescent
P-gp substrate) intracellular accumulation after 30 min, Si306 and its prodrug considerably inhibited
P-gp activity, while dasatinib did not show a similar activity (Figure 2c).
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cells after 72 h treatment with 5 µM Si306, pro-Si306 and dasatinib. (c) Flow-cytometric profile of Rho
123 accumulation after 30 min treatment with 5 µM Si306, pro-Si306 and dasatinib in U87-TxR cells.
Next, we determined the concentration of c-Src inhibitors necessary to inhibit P-gp activity by
50% (IC50 of P-gp inhibition, Tabl 2) We examined t e accumulation of Rho 123 in sensiti e -U87
and MDR-U87-TxR GBM cells after 30 min and comp red this accumulation w th that obtained fter
treatment with increasing concentratio s of Si306 and pro-Si306 (Figure 3). The effects were compared
with those promoted by the well-known P-gp inhibitors tariquidar (TQ) and Dex-verapamil (Dex-VER)
at the same TK inhibitor concentrations. Si306 and pro-Si306 led to the inhibition of P-gp function in
a concentration-dependent mann r illustrated by the progressive increase in Rh 123 accumula ion
(Figure 3).
The methodology used for the calculation of IC50 values for P-gp inhibition is described in detail
in Figure S1.
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Figure 3. Dose-dependent inhibition of P-gp function. Rho 123 accumulation in U87-TxR cells
(values expressed as mean fluorescence intensity ± S.D.) was assessed after application of different
concentrations of Si306, pro-Si306, Dex-VER (1, 2, 5, 10, 20 µM) and TQ (1, 2, 5, 10, 20 nM). The mean
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Rho 123 accumulation of sensitive cells—U87 was set as the upper limit (166), while the mean Rho
123 accumulation of MDR cells—U87-TxR was set as the lower limit (65). IC50 values were calculated
between these two limits. Two independent experiments were performed (a minimum of 10,000 events
was collected for each experimental sample). The significant difference to the lower limit (Rho 123
accumulation in U87-TxR cells) is expressed as: **, p < 0.01; ***, p < 0.001.
The IC50 values of P-gp inhibition for Si306 and pro-Si306 were 8.5 µM and 3.8 µM, respectively
(Table 2). TQ and Dex-VER did not display a dose-dependent effect as their first applied concentration
surpassed the calculated IC50 values of 0.3 nM and 0.7 µM, respectively (Figure 3 and Table 2).
Table 2. P-gp inhibition calculated by Rho 123 accumulation in cell.
P-gp Inhibition TQ a Si306 Pro-Si306 Dex-VER
IC50 (µM) 0.343 ± 0.017 8.496 ± 0.161 3.748 ± 0.060 0.735 ± 0.029
IC50 ± S.D. (n = 3); a IC50 ± S.D. values for tariquidar (TQ) are expressed in nM
2.3. Reversion of Paclitaxel Resistance by c-Src Inhibitors
Considering the potential of Si306 and pro-Si306 to inhibit P-gp function, we examined their
ability to reverse paclitaxel (PTX) resistance in U87-TxR cells (Figure 4 and Table 3).
The effects of the simultaneous combination of our compounds with PTX were assessed by the
MTT assay. Both c-Src inhibitors applied at low concentrations (0.2 µM and 0.5 µM) enhanced the PTX
efficacy, as indicated by a significant increase in the relative reversal index (Table 3).
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Table 3. Relative reversal of PTX resistance in 87- x cells i ce Si306 and pro-Si306.
pounds I 50 S.D. for PXT (µM) Relative e r
2.840 ± 0.358
Si306
0.2 µM 2.449 ± 0.121 1.16 ns
0.5 µM 0.850 ± 0.088 3.34 **
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0.2 µM 0.635 ± 0.103 4.47 ***
0.5 µM 0.356 ± 0.072 7.98 ***
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2.4. Si306 and pro-Si306 Interaction with CYP3A4 in Human Liver Microsomes
Si306 and pro-Si306 interaction with CYP3A4 isoform has been evaluated in vitro using testosterone
as probe through the quantification of its CYP-3A4 metabolite 6β-hydroxytestosterone in presence or
absence of different concentrations (1–50 µM range) of Si306 and pro-Si306. At the highest concentration
used the maximum of inhibition (20%, not significative) was promoted by Si306, while pro-Si306
inhibited the testosterone hydroxylation at a lower concentration (−15%) (Figure 5a). Ketoconazole
was used as standard CYP3A4 inhibitor to validate our method [51] (Figure 5b).
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Table 4. Plasmatic proteins binding parameters for Si306 and pro-Si306.
Compounds Parameters Si306 Pro-Si306
HSA
KD a (µM) 0.35 ± 0.1 21.45 ± 4.5
BMAX b 61.05 ± 2.8 78.00 ± 4.2
AGP
KD (µM) 11.49 ± 1.0 9.28 ± 0.7
BMAX 88.38 ± 1.8 96.69 ± 1.5
a Ligand concentration that binds to half the receptor sites at equilibrium; b maximum number of binding sites.
2.6. Pharmacokinetics and Biodistribution of Si306 After i.v. and per os Administration
A pharmacokinetic and biodistribution study was performed in order to further investigate if the
observed in vitro inhibitory activity of Si306 against P-gp could significantly affect its gastrointestinal
(GI) absorption and its brain penetration. For this purpose, the PK profile of Si306 was studied after
i.v. and p.o. administration. Si306 was administrated as a single dose at 25 mg/kg and 50 mg/kg
i.v. and p.o. in a final volume of 200 µL and 400 µL of vehicle, respectively. Blood and organs were
collected from mice and the concentration of Si306 was determined by HPLC-MS analysis. Table 5
shows the recovery and matrix effect data, which suggest that the developed analysis method could be
successfully applied to the pharmacokinetic and biodistribution studies for Si306.
Table 5. Matrix effect and recovery of Si306 in mice plasma, brain, liver and kidneys (n = 3).
µg/mL
Matrix Effect (%) Recovery (%)
Plasma Brain Liver Kidneys Plasma Brain Liver Kidneys
0.1 150 - - - 102.6 - - -
1 139.3 137.9 118.8 99.0 84.7 76.7 80.7 89.7
10 140.2 - - - 73.4 - - -
50 142.1 87.9 112.9 92.2 70.5 111.6 70.2 86.0
100 - 88.2 106.3 101.2 - 123.1 85.3 80.8
The plasma concentration of Si306 has been reported in Figure 7, while the corresponding PK
parameters are shown in Table 6.
Following oral administration, Si306 was rapidly absorbed with a Cmax of 2.97 µg/mL after 1.5 h
(Tmax) while the observed Cmax for i.v. treatment was 8.5 times higher. However, either AUC and MRT
showed similar values after the two different administration (see Table 6). The plasma half-life (t1/2)
also remains in the same range of values being 5.15 h and 5.96 h after i.v. and p.o. administration,
respectively. Moreover, the oral bioavailability of Si306 has been estimated as 33.3% using the following
equation (1), confirming a good absorption level from the GI apparatus.
Fp.os = [(AUCp.os x Di.v.)/(AUCi.v. x Dp.os)] × 100 (1)
In both cases, Si306 was able to reach the brain. In particular, after i.v. injection, the maximum
concentration into the brain (2.94 µg/g) has been detected immediately after 5 min, indicating a faster
penetration of the BBB (Figure 7a). Interestingly, after oral administration a large amount of Si306 has
been detected (10.65 µg/g) into the brain after 30 min, then the concentration slowly decreased during
the next 24 h (Figure 7b). Moreover, the AUC brain to plasma ratio parameter confirmed the brain
distribution to be greater for the oral route (1.185) with respect to i.v. (0.095).
An immediate distribution followed by a fast concentration decrease in a time-dependent manner
was also observed for liver and kidneys when Si306 was administered intravenously (Figure 7a).
On the other hand, orally administered Si306 showed its Cmax in liver and kidneys at 1.5 h and 2 h
respectively (Figure 7b).
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Table 6. Plasma and brain pharmacokinetic parameters for Si306 a.
Parameters Unit PLASMA BRAIN
Route i.v. p.o. i.v. p.o.
Dose mg/kg 25 50 25 50
Cmax b µg/mL 25.45 2.97 2.94 10.65
Tmax c h 0.08 1.5 0. 8 0.5
MRT d 0→∞ h 3.78 5.70 1.48 1.20
AUC e 0→∞ µg/mL × h 22.75 15.17 2.15 17.97
AUC e 0→24 h µg/mL × h 22.30 14.48 2.14 17.96
V f z/F L/Kg 8.17 28.32 44.04 8.44
CL g z/F L/h/Kg 1.10 3.29 11.60 2.78
t1/2 h h 5.15 5.96 2.63 2.10
a Calculated with PKSolver; b Cmax: maxi um concentration observed. c Tmax: time of maxi um concentration
observed. d MRT: mean residence time. e AUC: area under the curve. f V: volume of distribution. g CL: clearance.
h t1/2: half-life. Pharmacokinetic data were evaluated using a non-compartment model.
2.7. Acute Toxicity Study in Mice
The acute toxicity study provided useful information concerning the effect of acute exposure of
test animals to high doses of the compound under investigation. Treatment of mice with Si306 did not
produce treatment-related mortality at the limit test dose (100 mg/kg), and besides, throughout the four
days observation period, no significant changes occurred in the behavior, such as apathy, hyperactivity,
vomiting, diarrhea, and morbidity, among the tested animals. Thus, Si306 was found to be safe at the
dose level of 100 mg/kg and consequently, the LD50 value for i.v. toxicity is considered to be more
than 100 mg/kg. During the experiment, all animals were examined daily for any clinical signs and no
behavioral alteration such as motor activity, posture or autonomic features were observed. The body
weights of all mice recorded before the experiment and once every day after the treatment showed no
significant changes. No microscopic alterations were found in the main metabolic organs (liver and
kidney) and in the target organ of the drug (central nervous system) in treated versus untreated mice
(Figure 8).
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3. Discussion
In the last ten years, pharmaceutical research in oncology has produced many agents targeting
important pathways that are considered as being crucial for the development and progression of
different tumor types. Although these targeted agents have shown impressive preclinical results,
the real clinical benefits have not been as satisfying as expected. It is clear that a great deal of
effort was invested into understanding the molecular mechanisms involved in cancer development,
while the evaluation of drug interactions with cellular components different from the target molecule
was neglected.
New TKIs are being approved from the FDA each year on a regular basis [53], either given alone
or in combination with conventional chemotherapeutics. Although TKIs have revolutionized cancer
therapy, increasing resistance to TKIs has been documented [54]. Enhanced eﬄux of TKIs due to the
over-expression of P-gp and BCRP in cancer cells is usually responsible for the poor chemotherapeutic
response [55–57]. Accumulating evidence continues to show that numerous TKIs are substrates of
P-gp, so once they are entered into the cells, they are pumped out by ABC transporters [58]. Therefore,
the ability of a TKI drug to inhibit P-gp is considered as an important feature for successful anticancer
treatment, especially in the case of GBM, whose therapy is additionally compromised by the presence
of the BBB.
Recently, we reported an exploratory pharmacokinetic study after i.p. injection of Si306 and
pro-Si306 [50]. The data showed a prolonged overall exposure to the active Si306 after the injection of the
prodrug, probably due to the slow hydrolysis into the blood of pro-Si306. The concentration of prodrug
quantified into the brain was found higher than the quantity of Si306 measured in the brain of mice
treated only with the free drug. Moreover, in comparison to the parental drug, after p.o. administration,
pro-Si306 demonstrated a comparable efficacy with a slightly increasing median survival time of mice
in an orthotopic GBM model [50]. Finally, the PK profile of pro-Si306 administrated p.o. was evaluated.
Differently from i.p. injection, pro-Si306 was detected neither into the plasma nor in the brain, probably
because of a complete hydrolysis occurred into the GI tract [50].
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Considering the results obtained in our previous study, herein we decided to evaluate the effect
of Si306 and pro-Si306 on P-gp eﬄux pump, which accounts for GI absorption and BBB penetration
of different substrates, including anticancer drugs and TKIs. The effect of our compounds has
been investigated compared with a reference compound, the well-known TKI dasatinib. The cell
growth inhibition reported for dasatinib ranges between 7 and 50 µM in GBM cell lines [59]. These
concentrations are above those clinically relevant. We showed that the novel c-Src inhibitor Si306 and
its prodrug possess higher cell growth inhibitory potential with almost double efficacy in comparison
with dasatinib. In addition, the effect of Si306 and pro-Si306 was not affected by the presence of
MDR phenotype. Both compounds did not change the P-gp expression at mRNA and protein level,
differently from dasatinib. Indeed, after 72 h treatment, dasatinib increased P-gp expression. This
implies that the application of our novel c-Src inhibitors could not further increase P-gp expression
in MDR GBM cells. Moreover, Si306 and pro-Si306 induced significant suppression of P-gp activity
and their effect was dose-dependent. They directly interacted with P-gp, showing significant P-gp
inhibition after 30 min of treatment.
Other authors reported transient decrease of P-gp expression achieved by 1 µM dasatinib after
24 h in MCF-7 (MCF-7/Adr) cell line, reversing its MDR to doxorubicin after 72 h. This effect on
P-gp expression enabled reversal of doxorubicin resistance by 3.35-fold when 0.5 µM dasatinib was
applied for 72 h. Dasatinib inhibited the cell growth of (MCF-7/Adr) with low efficacy, reaching
IC50 at 40 µM [60]. In our experimental setting of 72 h simultaneous combined treatment, 0.5 µM of
Si306 and pro-Si306 reverted PTX resistance in MDR GBM cells by 3.34 and 7.98-fold, respectively.
The sensitization of U87-TxR cells was achieved by concentrations that were significantly lower
than those necessary for the optimal cell growth inhibition or P-gp inhibition induced by Si306 and
pro-Si306. Therefore, even sub-cytotoxic concentrations of new c-Src inhibitors were able to increase
PTX intracellular accumulation by inhibiting P-gp. It is possible that the inhibitory effect of drug and
prodrug on P-gp activity increases over time enabling the enhancement of PTX efficacy. Stronger effects
regarding P-gp inhibition and reversal of PTX resistance were observed after pro-Si306 application,
indicating a more potent activity of prodrug against P-gp.
Human cytochrome P450 is a family of enzymes responsible for the essential biotransformation of
xenobiotics [61]. Both P-gp and cytochrome P450 are involved in the first line of xenobiotic defense
system, sometimes referred to as a cellular ADME system [62]. In addition, drug metabolism via the
cytochrome P450 system has emerged as an important determinant in the occurrence of several drug
interactions that can result in drug toxicity, reduced pharmacological effect, and adverse drug reactions.
Predominant isoforms of cytochrome P450 involved in drug metabolism are CYP2C9, CYP2D6 and
CYP3A4 which metabolize up to 80–90% of all xenobiotics [63–66]. In particular, it has been estimated
that CYP3A4 metabolizes up to 50% of all reported drugs and a few of them are also metabolized by
other isoforms. In the liver and small intestine, p-glycoprotein and CYP3A4 are both expressed and
create a functional drug eﬄux-metabolism “alliance”, which establishes an absorption barrier against
xenobiotics [67]. Moreover, it was shown that the second generation of P-gp inhibitors are metabolized
by CYP3A4, thus competing with anticancer drugs for CYP-mediated clearing, finally leading to the
adverse toxicity [62,68]. Coordinately, it is important to elucidate whether P-gp inhibitors (Si306 and
its prodrug) may interact with cytochrome P450. Testosterone hydroxylation is in general used today
as one of the characteristic assays for testing the inhibition of P450 isoform 3A4. The major product of
testosterone metabolism is 6β-hydroxytestosterone but several other hydroxylations occur, including
those at the 2β and 15β positions [69–71]. The evidence that the testosterone 6β-hydroxylation is not
also inhibited by the two compounds at the highest concentration used clearly indicates that both Si306
and its prodrug did not interact with the CYP3A4.
It is well-known that drug permeability through biological membranes depends on factors such
as plasma protein-binding, hydrophobicity and molecular size of the drug. Among these factors,
protein-binding of the drug, which is closely-related to hydrophobicity, plays an important role in
drug pharmacokinetics and pharmacodynamics. HSA is the major protein component of blood plasma
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(about 60%) and binds a number of relatively insoluble endogenous compounds. AGP primarily binds
basic drugs (e.g., amines) and it is also reported to bind hydrophobic compounds [72]. For these
reasons, the binding to albumin and alpha 1-acid glycoprotein of Si306 and pro-Si306 was evaluated.
Both pro-Si306 and its parental drug Si306 showed high affinity for HSA and AGP plasmatic proteins
(drugs that are highly bound are characterized by a KD value less than 100 µM). For AGP, KD values
for Si306 and pro-Si306 were comparable, both being weak basic compounds. On the other hand,
the very poorly water soluble [50] Si306 displayed a very high affinity for albumin, 60-fold greater
than pro-Si306. This feature may suggest a plasmatic large fraction of bound drug, which could be the
reason for its slow plasma clearance kinetics.
From our previous study, pro-Si306 emerged as an effective potential drug against GBM, but
unfortunately is not suitable for an oral administration due to the complete hydrolysis into the GI
apparatus (mainly stomach) [50]. On the other hand, Si306 can be administrated p.o. and this is one of
the most important advantages in the use of TKIs, offering logistic flexibility and a good compliance in
patients [73].
To prove that Si306 could be considered a good drug candidate for the treatment of GBM
that is worthy of further development, a PK study after p.o. administration and i.v. injection has
been performed.
The peak plasma concentration of Si306 was observed at 5 min for i.v. and 1.5 h for p.o. The
plasma half-life (t1/2) resulted comparable between the two routes of administration and the oral
bioavailability of Si306 has been estimated around 33.3% in mice, being higher than that reported
for dasatinib (14% in mice) [74]. After both i.v. and p.o. administration Si306 was able to reach the
brain and pass the BBB. In particular, after i.v. injection the maximum concentration into the brain
(2.94 µg/g, Table 6) was observed after 5 min, while after oral administration a large amount of our
drug has been detected (10.65 µg/g, Table 6) into the brain after 30 min. In both cases, the concentration
of the compound slowly decreased during the next 24 h. Overall, our new results demonstrated a
good absorption of Si306 by GI and, most interestingly, an optimal brain penetration, with a 12-fold
higher AUC brain/plasma when Si306 was orally administered with respect to the i.v. injection. The
higher and very fast brain accumulation of oral Si306 could be related to the greater inhibition of p-gp,
and possibly saturation of p-gp sites at the BBB, which could be simply a consequence of the orally
administrated dose, which was twice that of the i.v. [75].
In this context, being the Si306 considered able to block intestinal p-gp and since direct inhibition
of p-gp in the small intestine was found to improve the oral bioavailability of p-gp substrates
(dramatic increase in intestinal absorption of paclitaxel was observed when p-gp inhibitors were
co-administrated [75]), the idea of combination with other drugs substrates of p-gp could be proposed.
Finally, in order to verify the safety of Si306 in vivo, an intravenously single-dose toxicity study
was performed. The compound was very well tolerated by mice, even at a high dose (100 mg/Kg).
Moreover, no mortality or changes in animal behavior were observed following the administration.
At fourth day from the injection of Si306, mice were sacrificed, and their organs were analyzed. Any
microscopic difference in the architecture of the main metabolic organs was observed, indicating very
good tolerability and a lack of acute toxicity.
4. Materials and Methods
4.1. Drugs
A pyrazolo[3,4-d]pyrimidine derivative Si306 as well as its prodrug, pro-Si306, were previously
synthesized and characterized [50]. Dasatinib as well as PTX and Dex-VER were purchased from
Sigma-Aldrich (Milan, Italy and Taufkirchen, Germany suppliers). Dr. Sven Rottenberg from The
Netherlands Cancer Institute in Amsterdam kindly provided TQ for our research purposes. Aliquots
of 20 mM of both Si306 and pro-Si306 were dissolved in dimethyl sulfoxide (DMSO) and kept at room
temperature. TQ was also dissolved in DMSO (10 µM stocks) but kept at −20 ◦C. PTX aliquots were
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stored at −20 ◦C in absolute ethanol (1 mM), while sterile water dilution of Dex-VER was kept at room
temperature. Immediately before treatments, the aforementioned drugs were diluted in sterile water.
4.2. Cells and Culture Conditions
Human GBM cell lines U87 and LN-229 were purchased from the American Type Culture
Collection, Rockville, MD, USA. U87-TxR cells were selected from U87 cells by continuous exposure
to increasing concentrations of PTX [76]. LN-299, U87 and U87-TxR cells were grown in Minimum
Essential Medium with 10% fetal bovine serum, 2 mM L-glutamine and 5000 U/mL penicillin, 5 mg/mL
streptomycin solution. Cell lines were maintained at 37 ◦C in a humidified 5% CO2 atmosphere. They
were sub-cultured at 72 h intervals using 0.25% trypsin/EDTA and 16,000 cells/cm2 were seeded into a
fresh medium.
4.3. MTT Assay
MTT assay was used to assess the viability of U87 and U87-TxR cells (AppliChem GmbH,
Taufkirchen, Germany). After reaching the confluence in 25 cm2 tissue flasks, U87 and U87-TxR
cells were trypsinized. Cells were seeded at the optimal density determined in initial experiments:
4000 cell/well into flat-bottomed 96-well tissue culture plates. Following the overnight incubation, cells
were treated with Si306, pro-Si306 and dasatinib (1–25 µM) for 72 h. In addition, the combined effects
of Si306 and pro-Si306 with PTX were evaluated in MDR GBM cells. To that end, two concentrations
of Si306 and pro-Si306 (0.2 µM and 0.5 µM) were combined with increasing concentrations of PTX
(0.1–2 µM) in simultaneous treatment. The sensitization of U87-TxR cells to PTX was studied after
72 h. Briefly, MTT was added to each well in a final concentration of 0.2 mg/mL for 4 h to induce the
formation of the formazan in cells with intact/viable mitochondria. Then, produced formazan was
dissolved in DMSO, and the absorbance was measured at 540 nm on a microplate reader (LKB 5060-006
Micro Plate Reader, Vienna, Austria). IC50 values were calculated by nonlinear regression analysis
using GraphPad Prism 6.0 for Windows (GraphPad Software, La Jolla, CA, USA).
4.4. RNA Extraction and Reverse Transcription (RT) Reaction
U87-TxR cells, untreated and treated with 5 µM of each compound Si306, pro-Si306 and dasatinib
for 72 h were used to isolate total RNA and perform the RT reaction. Isolation was done by using
Trizol® reagent (Invitrogen Life Technologies, Waltham, MA, USA). Quantification of RNA and its
quality determination were performed by spectrophotometry and by agarose gel electrophoresis,
respectively. For the RT reactions, 2 µg of total RNA were used, while a high-capacity cDNA reverse
transcription kit (Applied Biosystems, Waltham, MA, USA) was employed.
4.5. Quantitative Real-Time PCR
To assess mRNA mdr1 expression level in U87-TxR cells upon 5 µM Si306, pro-Si306 and dasatinib
treatments, the quantitative real time PCR (qRT-PCR) was used. The PCR reactions according to the
manufacturer’s recommendations were performed in the presence of 100 ng cDNA combined with
primers specific for MDR1 and ACTB, as an internal control for normalization [77,78], and a Maxima
SYBR Green/ROX qPCR Master Mix (Thermo Scientific, Waltham, MA, USA) on an ABI PRISM 7000
Sequence Detection System (Applied Biosystems, Waltham, MA, USA). Analyses of triplicate samples
in terms of relative gene expression were completed using the 2−∆∆Ct method [79].
4.6. Flow-Cytometric Analysis of P-Glycoprotein Expression
To assess the P-glycoprotein expression level in MDR GBM cells, flow-cytometry was employed.
U87-TxR cells seeded in adherent 6-well plates were treated with 5 µM Si306, pro-Si306 or dasatinib for
72 h. Then, cells were collected by trypsinization, washed in PBS, and then directly immuno-stained
by FITC-conjugated anti-P-gp antibody (BD Biosciences, Winnersh, Berkshire, UK). To discriminate the
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level of background fluorescence, an isotype control IgG2bκ (Abcam, Cambridge, United Kingdom)
was used. The fluorescence of FITC-conjugated anti-P-gp was analyzed on assessed on the fluorescence
channel 1 (FL1) of the CyFlow Space Partec flow-cytometer (Sysmex Partec GmbH, Görlitz, Germany).
After gating to exclude the cell debris and dead cells, a minimum of 10,000 cells per sample was
assayed. Summit Dako Software was used for the analyses of results obtained by flow-cytometry.
4.7. Rho 123 Accumulation Assay
Rho 123 accumulation was analyzed by flow-cytometry utilizing the ability of Rho 123, which is a
substrate for P-glycoprotein, to emit fluorescence. The intensity of the fluorescence is proportional to
Rho 123 accumulation in the cell. Studies were carried out with Si306, pro-Si306, dasatinib, Dex-VER
and TQ in U87-TxR cells. U87 cells were used as a positive control for Rho 123 accumulation.
In simultaneous treatment that lasted 30 min, 5 µM Rho 123 was applied along with 5 µM of Si306,
pro-Si306 and dasatinib. To obtain IC50 values for P-gp inhibition, 5 µM Rho 123 was simultaneously
applied with the increasing concentrations of Si306, pro-Si306, Dex-VER (1, 2, 5, 10 and 20 µM) and
TQ (1, 2, 5, 10 and 20 nM). Samples were incubated 30 min at 37 ◦C in 5% CO2. At the end of
the accumulation period, the cells were pelleted by centrifugation, washed with PBS and placed in
cold PBS. The samples were kept on ice in a dark setting until the analysis on CyFlow Space Partec
flow-cytometer (Sysmex Partec GmbH, Germany). The orange fluorescence of Rho 123 was assessed on
fluorescence channel 2 (FLH-2) at 585 nM. A minimum of 10,000 events was assayed for each sample
and the obtained results were analyzed using Summit Dako Software (ver. 4.3, Fort Collins, CO, USA).
4.8. Data Collection and Statistical Methods
Statistical analyses for P-gp inhibition and combination treatments were performed by two-way
ANOVA test (GraphPad Prism 6 software) using Dunnett’s multiple comparisons test. Statistical
significance was accepted if p < 0.05.
4.9. Binding Fluorimetric Assay
In order to determine the binding affinity for Si306 and pro-Si306 to HSA (human serum albumin)
and AGP (alpha-1-acid glycoprotein), the protein fluorescence has been monitored by spectroscopy. The
quantitative analysis was performed using black 96 multiwell plates: in each well, a fixed concentration
of HSA or AGP (10 µM in phosphate buffer 1 mM) was added with different amounts of the tested
compound (0.1 µM to 500 µM). Plates were gently shacked and after 30 min at room temperature
for equilibration, spectra were recorded from 300 to 400 nm, after excitation at 295 nm, by using a
Perkin Elmer EnVision Multilabel Reader 2014 spectrofluorimeter. Finally, spectra were acquired with
EnVision Manager ver.1.13 software (Walthman, MA, USA). The obtained non fluorescence quenching
percentages were plotted against drug concentrations and the relative KD values were calculated using
GraphPad software (version 6.0).
4.10. CYP450 Inhibition Study
The inhibition of cytochrome P450 3A4 isoform by Si306 and pro-Si306 was measured by
determining its activity on the substrate testosterone.
The activity of CYP3A4 was evaluated by measuring the 6β-hydroxylated testosterone formation
(CYP3A4-specific reaction). The amount of 6β-hydroxylated metabolite was assessed in the absence
and presence of Si306, pro-Si306 and ketoconazole (testosterone concentration of 100 µM in phosphate
buffer 0.025 M, pH 7.4). The compounds were solubilized in DMSO and added in a test tube to give
final concentrations 1, 10, 25, 50 and 0.01, 0.05, 0.5, 5 µM, (DMSO did not exceed 2%). Ketoconazole
was used as standard selective inhibitor of CYP3A4 isoenzyme [55]. Incubations were carried out in a
mix containing human liver microsomes (1 mg/mL of protein) in phosphate buffer 0.025 M, pH 7.4,
NADPH (200 µM) previously solubilized in a MgCl2 48 mM solution. The final incubation volume
was 0.25 mL. After a 40 min-incubation period at 37 ◦C, the reaction was stopped by adding 1 mL of
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acetonitrile in the presence of corticosterone 2 µM as internal standard. The samples were centrifuged
for 20 min at 5000 rpm. Concentrations of testosterone and its metabolite 6β-hydroxytestosterone
were assessed by the HPLC method with UV detection. Calibration curve for quantitative analysis
of 6β-hydroxytestosterone in the samples was obtained using commercial 6β-hydroxytestosterone
purchased from Sigma Aldrich. For the statistical analysis, GraphPad InStat 3.0 (GraphPad Software,
San Diego, CA, USA) was used.
4.11. Animals
4.11.1. For PK and BD Studies
Naive male BALB/C mice (weight 20 ± 2 g) were ordered from Charles River (Milan, Italy).
All animals were pathogen free and approximately 4–6 weeks old when they arrived. The adaption
period to the environment was not less than seven days. All the procedures used on animals in this
study were approved by Institutional Animal Use and Care Committee at Università Cattolica del S.
Cuore, Rome and Università degli Studi di Siena and authorized by the Italian Ministry of Health,
according to Legislative Decree 116/92, which implemented the European Directive 86/609/EEC on
laboratory animal protection in Italy. Methods for all the conducted experiments were performed
in accordance with regulations, standards and guidelines of the Animal Use and Care Committee of
Università Cattolica del S. Cuore, Rome and Università degli Studi di Siena.
4.11.2. For Acute Toxicity Studies
Male BALB/c mice (20 ± 2) g, supplied by Harlan Italy S.r.l., San Pietro al Natisone, Udine, Italy,
were acclimated at 25 ◦C and 55% of humidity under natural light/dark conditions for 1 week before
the proposed experiments. Animal welfare was routinely checked by veterinarians of the Service for
Animal Welfare and all efforts were made to minimize suffering.
4.12. In Vivo Administration of Si306
Si306 was dissolved in a mixture of Tween80 (10% v/v), benzyl alcohol (1% v/v) and a 10 mM
solution of citric acid. The compound was administered intravenously as a single dose of 25 mg/kg in
200 µL of volume. At several time points (0.08, 0.25, 0.5, 1, 2, 4, 8, 24 h), after drug administration,
mice were treated i.p. with heparin (5000 U/kg) and sacrificed under CO2. Five animals were used
for each time point. Blood, brain, liver and kidneys were collected for the following quantitative
analysis. Approximately 500–600 µL of blood was collected from each animal and transferred to a tube
containing 10 µL of heparin and mixed briefly.
For the oral PK studies, mice received a single dose of 50 mg/kg of Si306 (dissolved in the same
vehicle used for i.v. studies) in 400 µL of final volume by gavage. At nine time-points (0.25, 0.5, 1, 1.5,
2, 3, 4, 8, 24 h) after administration, mice were sacrificed under CO2. Blood and organs were collected
and analyzed by LC-MS. The pharmacokinetic parameters, including area under concentration-time
curve (AUC), maximum plasma concentration (Cmax), half-time (t1/2), apparent volume of distribution
(V), plasma clearance (CL) and mean residence time (MRT), were calculated by non-compartmental
analysis using PKSolver software (ver. 1.0, Nanjing, China) [80].
4.12.1. Sample Preparation
Blood samples were centrifuged at 5000 rpm for 20 min to separate the plasma fraction, which
was subsequently collected in a test tube. Acetonitrile (1 mL, with Si34 as internal standard at the
concentration of 5 µg/mL) was added to each sample to denature proteins. Samples were centrifuged
at 5000 rpm for 20 min, and the supernatant was recovered, dried under vacuum, solubilized again in
methanol (100 µL), and analyzed. Brain and the other organs were homogenized using a T10 basic
ULTRA-TURRAX® homogenizer (Bioclass, Pistoia, Italy); in order to extract the compound from
the tissue, acetonitrile internal standard solution was added, and the homogenate was centrifuged
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at 5000 rpm for 20 min. The supernatant was recovered, filtered and analyzed by LC-MS. The
quantification of each compound was performed by reference to the appropriate calibration curve.
Representative LC-MS chromatograms for Si306 and for Si34 are reported in Figure S2 and Figure S3
respectively. Mass spectra are also shown in Figure S4.
4.12.2. Recovery and Matrix Effect
The matrix effect was evaluated in samples by comparing the peak areas of the Si306 reference
solutions reconstituted in blank organ extracts (for plasma, brain, liver and kidneys) against those
of the analyte dissolved in mobile phase. The recovery of Si306 was evaluated by comparing the
peak area of Si306 in spiked plasma and other organs samples with the peak areas of analyte spiked
after extraction into plasma or organs’ extracts [81]. The matrix effect of the IS was evaluated in a
similar manner.
4.12.3. UV/HPLC-MS Instrumentation and Analysis Condition
LC analyses were performed by using Agilent 1100 LC/MSD VL system (G1946C) (Agilent
Technologies, Palo Alto, CA, USA) constituted by a vacuum solvent degassing unit, a binary
high-pressure gradient pump, a 1100 series UV detector, and a 1100 MSD model VL benchtop
mass spectrometer. MSD single-quadrupole instrument was equipped with the orthogonal spray
API-ES (Agilent Technologies, Palo Alto, CA, USA). The pressure of the nebulizing gas and the flow of
the drying gas (nitrogen used for both) were set at 40 psi, 9 L/min, respectively. The capillary voltage,
the fragmentor voltage, and the vaporization temperature were 3000 V, 70 V, and 350 ◦C, respectively.
MSD was used in the positive ion mode. Spectra were acquired over the scan range m/z 50–1500 using
a step size of 0.1. Chromatographic analysis for CYP3A4 interaction studies was performed using a
Phenomenex Luna C18 100A column (250 × 4.6 mm, 5 µm particle size) at room temperature, at flow
rate of 0.6 mL/min, and injection volume was 20 µL, operating with a gradient elution of acetonitrile
(ACN) and water (H2O): t = 0 min ACN 0%, t = 2 min ACN 0%, t = 40 min ACN 70%, t = 45 min ACN
70%, t = 50 min ACN 0%. UV detection was monitored at 254 nm. Chromatographic analysis for Si306
and its internal standard Si34 was performed using a Kinetex EVO C18 100A column (150 × 4.6 mm,
5 µm particle size) at room temperature, at flow rate of 0.6 mL/min, and injection volume was 20 µL,
operating with a gradient elution of acetonitrile (ACN) and water (H2O): t = 0 min ACN 0%, t = 3 min
ACN 0%, t = 12 min ACN 98%, t = 18 min ACN 98%. Representative LC-MS chromatograms and mass
spectra have been reported in Supporting Information.
4.13. Evaluation of Acute Safety Profile in Mice
The study design includes three groups of five mice each. All mice were injected with compound
through the tail vein in a single systemic dose (0.05 mL per dose). The test compound was solubilized
in PBS/25% DMSO. The first group was treated with dose levels of 50 mg/kg; the second received a
high-dose level of 100 mg/kg, whereas the third was inoculated with the only vehicle as the control.
All mice were monitored for survival and the presence of any drug-related adverse effect (local signs
of inflammation, weight loss, diarrhea, and behavioral alterations) throughout the experimental
period. Mice were sacrificed 4 days after treatment, and liver, kidney, and brain tissue specimens
were aseptically removed, fixed in 4% formaldehyde solution, and processed for paraffin embedding.
Histopathological changes in tissue specimens were evaluated in 10 randomly selected tissue sections
from each organ for all the samples. Sections cut at 2 µm were stained with hematoxylin and eosin
(H&E) and analyzed by a pathologist with an optical microscope (Leica, Wetzlar, Germany).
5. Conclusions
As a continuation of efforts in the development and optimization of new TKIs active against
GBM, in the present study we described the further in vitro and in vivo characterization of Src
inhibitor pyrazolo[3,4-d]pyrimidine derivatives. The identification of TKIs whose activity could not
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be affected by developed multidrug resistance mechanisms is an urgent need. The efficacy of many
TKIs is diminished by the fact that they are P-glycoprotein substrates. Herein, we showed that the
sensitivity of multidrug resistant GBM cells was not compromised by pyrazolo[3,4-d]pyrimidine
derivatives treatment. Moreover, we reported that Src inhibitors, Si306 and its prodrug possess
valuable characteristics for GBM treatment. Both compounds are able to suppress P-glycoprotein
activity without inducing its expression in multidrug resistant GBM cells. In addition, Si306 and
pro-Si306 do not interact with CYP3A4 and possess the ability of binding to plasma proteins. The
penetration of Si306 in mouse brain after oral administration was confirmed to be optimal, while
toxicology studies showed a good tolerability profile of this agent. All these features imply that the Src
inhibitor Si306 could be considered as a valuable strategy for GBM treatment alone or in combination
with other chemotherapeutics. Furthermore, Si306 could facilitate the accumulation of co-administered
drugs into the brain and GBM site, due to its high activity against P-gp present in BBB.
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